ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

Researchers have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results, the approach combined the benefits of ...

“In 2024, we delivered strong progress and continued momentum for our clinical development program evaluating evorpacept as a ...

Rentosertib is designed to treat IPF by targeting Traf2- and NCK-interacting kinase (TNIK), a serine/threonine kinase whose activation plays a crucial role in cellular processes that include signal ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...

The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing cancers.

Many solid tumors express the CD47 protein on their surface, which serves as a “don’t eat me” signal to the body’s immune system, allowing the tumor to evade detection. The antibody in this ATC ...